What is Parkinson's Phase 2B Study Pramipexole / Rasagiline Mesylate?

Category: Others

false

NCT01968460 is a twelve-week multi-Center, randomized, double-blind, placebo-controlled, parallel group study, to determine the safety, tolerability and efficacy of two doses of once daily P2B001 in subjects with early Parkinson's Disease.

Dosages

Based on patients currently using Parkinson's Phase 2B Study Pramipexole / Rasagiline Mesylate

Dosage Patients
1 mg daily 1

Duration

Currently using Parkinson's Phase 2B Study Pramipexole / Rasagiline Mesylate

Duration Patients
1 - 2 years 1

What people switch to and from

Patients started using Parkinson's Phase 2B Study Pramipexole / Rasagiline Mesylate after stopping:

Treatment Patients
Rasagiline (Azilect) 1
Last updated:
There are no evaluations for Parkinson's Phase 2B Study Pramipexole / Rasagiline Mesylate.